孕妇血液中游离DNA分析用于非整倍体筛查:更新的荟萃分析
该荟萃分析检索2011年1月至2016年12月间文献,纳入35项临床验证或实施研究,评估孕妇血浆游离DNA(cfDNA)筛查胎儿21、18、13三体及性染色体非整倍体的性能。结果显示,单胎妊娠中21三体检出率99.7%、假阳性率0.04%,18三体检出率97.9%,13三体检出率99.0%,合并假阳性率0.13%;性染色体非整倍体报告病例数过少,无法准确评估;双胎妊娠21三体检出率100%,但病例数少。
要点
- 单胎妊娠cfDNA筛查21三体检出率99.7%(95%CI 99.1-99.9%),假阳性率0.04%(95%CI 0.02-0.07%)。
- 单胎妊娠18三体检出率97.9%,13三体检出率99.0%,两者假阳性率均为0.04%。
- 性染色体非整倍体报告病例数过少,无法准确评估筛查性能;双胎21三体数据有限。
核心结论
- 单胎妊娠中,孕妇血液cfDNA分析筛查可检出>99%的21三体、98%的18三体和99%的13三体胎儿,合并假阳性率为0.13%。
- 性染色体非整倍体报告病例数过少,无法准确评估筛查性能。
- 双胎妊娠中21三体筛查性能令人鼓舞,但报告病例数少。
研究设计与样本
- 检索PubMed、EMBASE和Cochrane图书馆,纳入2011年1月至2016年12月31日间发表的同行评议文章。
- 纳入标准为报告临床验证或实施、且>85%研究人群有妊娠结局数据的同行评议研究。
- 排除病例对照研究、原理验证性文章及实验室人员知晓胎儿核型或妊娠结局的研究。
- 共纳入35项相关研究,采用双变量随机效应回归模型计算合并检出率和假阳性率。
主要发现
- 21三体:1963例病例和223932例非21三体单胎妊娠,合并检出率99.7%(95%CI 99.1-99.9%),假阳性率0.04%(95%CI 0.02-0.07%)。
- 18三体:563例病例和222013例非18三体单胎妊娠,合并检出率97.9%(95%CI 94.9-99.1%),假阳性率0.04%(95%CI 0.03-0.07%)。
- 13三体:119例病例和212883例非13三体单胎妊娠,合并检出率99.0%(95%CI 65.8-100%),假阳性率0.04%(95%CI 0.02-0.07%)。
- 单体X:36例病例和7676例未受累单胎妊娠,合并检出率95.8%(95%CI 70.3-99.5%),假阳性率0.14%(95%CI 0.05-0.38%)。
- 其他性染色体非整倍体:17例病例和5400例未受累单胎妊娠,合并检出率100%(95%CI 83.6-100%),假阳性率0.004%(95%CI 0.0-0.08%)。
局限性
- 性染色体非整倍体报告病例数过少,无法准确评估筛查性能。
- 双胎妊娠中21三体筛查性能令人鼓舞,但报告病例数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To review clinical validation or implementation studies of maternal blood cell-free (cf) DNA analysis and define the performance of screening for fetal trisomies 21, 18 and 13 and sex chromosome aneuploidies (SCA). METHODS: Searches of PubMed, EMBASE and The Cochrane Library were performed to identify all peer-reviewed articles on cfDNA testing in screening for aneuploidies between January 2011, when the first such study was published, and 31 December 2016. The inclusion criteria were peer-reviewed study reporting on clinical validation or implementation of maternal cfDNA testing in screening for aneuploidies, in which data on pregnancy outcome were provided for more than 85% of the study population. We excluded case-control studies, proof-of-principle articles and studies in which the laboratory scientists carrying out the tests were aware of fetal karyotype or pregnancy outcome. Pooled detection rates (DRs) and false-positive rates (FPRs) were calculated using bivariate random-effects regression models. RESULTS: In total, 35 relevant studies were identified and these were used for the meta-analysis on the performance of cfDNA testing in screening for aneuploidies. These studies reported cfDNA results in relation to fetal karyotype from invasive testing or clinical outcome. In the combined total of 1963 cases of trisomy 21 and 223 932 non-trisomy 21 singleton pregnancies, the weighted pooled DR and FPR were 99.7% (95% CI, 99.1-99.9%) and 0.04% (95% CI, 0.02-0.07%), respectively. In a total of 563 cases of trisomy 18 and 222 013 non-trisomy 18 singleton pregnancies, the weighted pooled DR and FPR were 97.9% (95% CI, 94.9-99.1%) and 0.04% (95% CI, 0.03-0.07%), respectively. In a total of 119 cases of trisomy 13 and 212 883 non-trisomy 13 singleton pregnancies, the weighted pooled DR and FPR were 99.0% (95% CI, 65.8-100%) and 0.04% (95% CI, 0.02-0.07%), respectively. In a total of 36 cases of monosomy X and 7676 unaffected singleton pregnancies, the weighted pooled DR and FPR were 95.8% (95% CI, 70.3-99.5%) and 0.14% (95% CI, 0.05-0.38%), respectively. In a combined total of 17 cases of SCA other than monosomy X and 5400 unaffected singleton pregnancies, the weighted pooled DR and FPR were 100% (95% CI, 83.6-100%) and 0.004% (95% CI, 0.0-0.08%), respectively. For twin pregnancies, in a total of 24 cases of trisomy 21 and 1111 non-trisomy 21 cases, the DR was 100% (95% CI, 95.2-100%) and FPR was 0.0% (95% CI, 0.0-0.003%), respectively. CONCLUSIONS: Screening by analysis of cfDNA in maternal blood in singleton pregnancies could detect > 99% of fetuses with trisomy 21, 98% of trisomy 18 and 99% of trisomy 13 at a combined FPR of 0.13%. The number of reported cases of SCA is too small for accurate assessment of performance of screening. In twin pregnancies, performance of screening for trisomy 21 is encouraging but the number of cases reported is small. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Gil MM, Accurti V, Santacruz B, et al. Analysis of cell-free DNA in maternal blood in screening for aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol. 2017. PMID: 28397325. doi:10.1002/uog.17484
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。